Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Advancements In Prophylactic And Therapeutic Nanovaccines

P. Bhardwaj, Eshant Bhatia, S. Sharma, N. Ahamad, R. Banerjee
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Abstract Vaccines activate suitable immune responses to fight against diseases but can possess limitations such as compromised efficacy and immunogenic responses, poor stability, and requirement of adherence to multiple doses. ‘Nanovaccines’ have been explored to elicit a strong immune response with the advantages of nano-sized range, high antigen loading, enhanced immunogenicity, controlled antigen presentation, more retention in lymph nodes and promote patient compliance by a lower frequency of dosing. Various types of nanoparticles with diverse pathogenic or foreign antigens can help to overcome immunotolerance and alleviate the need of booster doses as required with conventional vaccines. Nanovaccines have the potential to induce both cell-mediated and antibody-mediated immunity and can render long-lasting immunogenic memory. With such properties, nanovaccines have shown high potential for the prevention of infectious diseases such as acquired immunodeficiency syndrome (AIDS), malaria, tuberculosis, influenza, and cancer. Their therapeutic potential has also been explored in the treatment of cancer. The various kinds of nanomaterials used for vaccine development and their effects on immune system activation have been discussed with special relevance to their implications in various pathological conditions. Statement of Significance Interaction of nanoparticles with the immune system has opened multiple avenues to combat a variety of infectious and non-infectious pathological conditions. Limitations of conventional vaccines have paved the path for nanomedicine associated benefits with a hope of producing effective nanovaccines. This review highlights the role of different types of nanovaccines and the role of nanoparticles in modulating the immune response of vaccines. The applications of nanovaccines in infectious and non-infectious diseases like malaria, tuberculosis, AIDS, influenza, and cancers have been discussed. It will help the readers develop an understanding of mechanisms of immune activation by nanovaccines and design appropriate strategies for novel nanovaccines.
This paper references
De Berardinis , Vectorized delivery of alpha-galactosylceramide and tumor antigen on filamentous bacteriophage fd induces protective immunity by enhancing tumor-specific T Cell response
R Sartorius (2018)
10.1016/j.mib.2009.12.001
Polymeric particles in vaccine delivery.
A. Rice-Ficht (2010)
10.1128/mBio.01869-19
Development of a Gold Nanoparticle Vaccine against Enterohemorrhagic Escherichia coli O157:H7
Javier I. Sanchez-Villamil (2019)
10.1016/j.jconrel.2018.06.028
Immune responses induced by nano‐self‐assembled lipid adjuvants based on a monomycoloyl glycerol analogue after vaccination with the Chlamydia trachomatis major outer membrane protein
L. Rodrigues (2018)
10.1038/s41598-018-31089-y
Nanoscale Peptide Self-assemblies Boost BCG-primed Cellular Immunity Against Mycobacterium tuberculosis
C. Chesson (2018)
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition
E Hamilton (2012)
W
A. Badiee (2012)
10.1016/S0168-3659(02)00275-4
Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres.
Manish Diwan (2002)
10.1038/nri2868
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
M. Bachmann (2010)
10.1126/science.1251102
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
E. Tran (2014)
10.1038/nri2173
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting
P. Tacken (2007)
10.1093/neuonc/not203
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
O. Bloch (2014)
10.3389/fimmu.2014.00461
Toll-Like Receptor Signaling Pathways
T. Kawasaki (2014)
Immunisation with tumor neoantigens displayed on T7 phage nanoparticles elicits plasma antibody and vaccine-draining lymph node B cell responses
G S Shukla (2018)
10.3389/fimmu.2018.02224
Nanoparticle Vaccines Against Infectious Diseases
R. Pati (2018)
10.1016/j.biomaterials.2017.03.034
Synthetic vaccine nanoparticles target to lymph node triggering enhanced innate and adaptive antitumor immunity.
S. Kim (2017)
10.1002/adhm.201200268
Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective.
Jardin A Leleux (2013)
10.1073/pnas.1001074107
Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis
Haochu Huang (2010)
10.1088/0957-4484/21/19/195101
Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide.
Yangyang Chen (2010)
10.1038/nmat4822
Designer vaccine nanodiscs for personalized cancer immunotherapy
Rui Kuai (2017)
10.1371/journal.pone.0163539
A Triple Co-Culture Model of the Human Respiratory Tract to Study Immune-Modulatory Effects of Liposomes and Virosomes
Rebecca A. M. Blom (2016)
10.1021/mp2004059
Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen.
L. Petersen (2012)
10.1038/s41541-017-0024-6
Protein nanovaccine confers robust immunity against Toxoplasma
Kamal El Bissati (2017)
10.3390/vaccines2030515
Peptide Vaccine: Progress and Challenges
W. Li (2014)
10.1016/j.vaccine.2015.10.132
A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens.
Gokul Swaminathan (2016)
10.1038/nri3191
Adoptive immunotherapy for cancer: harnessing the T cell response
N. Restifo (2012)
10.1016/j.biomaterials.2017.09.017
Nanomaterials for cancer immunotherapy.
W. Song (2017)
1–21 chitosan nanoparticles as an efficient delivery vehicle for Mycobacterium tuberculosis lipids to induce potent cytokines and antibody response through activation of gammadelta T cells
I. Das (2020)
10.1096/fj.12-218362
Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood‐stage human malaria vaccine
Kae Pusic (2013)
10.1002/adma.201901255
Biomimetic Nanotechnology toward Personalized Vaccines.
J. Zhou (2019)
10.1016/j.vaccine.2017.12.053
A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles.
A. Ramírez (2018)
10.1016/j.biomaterials.2009.05.075
Memory antibody response from antigen loaded polymer particles and the effect of antigen release kinetics.
V. Kanchan (2009)
10.1189/jlb.5RI0315-096R
Trained innate immunity as underlying mechanism for the long‐term, nonspecific effects of vaccines
Bastiaan A. Blok (2015)
10.1021/nn200182x
Single-Walled Carbon Nanotubes Deliver Peptide Antigen into Dendritic Cells and Enhance IgG Responses to Tumor-Associated Antigens
C. Villa (2011)
R
B. A. Blok (2015)
10.1021/acs.bioconjchem.7b00761
Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy.
Rui Kuai (2018)
10.1016/j.biomaterials.2016.01.056
Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses.
Nicholas M. Molino (2016)
10.1016/j.jconrel.2012.10.020
Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses.
S. Rizwan (2013)
10.1088/1361-6528/aa60fd
Biocompatible chitosan nanoparticles as an efficient delivery vehicle for Mycobacterium tuberculosis lipids to induce potent cytokines and antibody response through activation of γδ T cells in mice.
Ishani Das (2017)
R
C. Keijzer (2013)
10.1016/j.jconrel.2019.02.036
Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy.
Min Luo (2019)
10.1371/journal.pone.0061135
Enhanced Immune Response and Protective Effects of Nano-chitosan-based DNA Vaccine Encoding T Cell Epitopes of Esat-6 and FL against Mycobacterium Tuberculosis Infection
Ganzhu Feng (2013)
10.1186/1479-5876-10-28
Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
E. Hamilton (2011)
Immunisation with tumor neoantigens displayed on T7 phage nanoparticles elicits plasma antibody and vaccinedraining lymph node B cell responses
G. S. Shukla (2018)
10.1186/s12951-015-0119-z
Design and optimization of peptide nanoparticles
T. A. Doll (2015)
10.1021/ACSABM.8B00811
Dendritic Cell Targeting Peptide-Based Nanovaccines for Enhanced Cancer Immunotherapy
Yating Liu (2019)
10.1021/nn5054206
Nanomimics of host cell membranes block invasion and expose invasive malaria parasites.
A. Najer (2014)
10.1016/j.immuni.2010.03.015
Reversal of autoimmunity by boosting memory-like autoregulatory T cells.
Sue Tsai (2010)
10.2147/IJN.S109098
Green synthesis and evaluation of silver nanoparticles as adjuvant in rabies veterinary vaccine
V. Asgary (2016)
10.1021/ja4046857
‘Multicopy Multivalent’ Glycopolymer-Stabilized Gold Nanoparticles as Potential Synthetic Cancer Vaccines
A. L. Parry (2013)
10.1002/btm2.10005
Engineering nanoparticles to overcome barriers to immunotherapy
R. Toy (2016)
10.2147/IJN.S40238
Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles
D. Dhanasooraj (2013)
10.1021/nl300027p
Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment.
Ligeng Xu (2012)
10.4324/9780203379950-24
{m
Kaushalya Madhawa (2020)
10.1016/j.biomaterials.2014.10.053
CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
Rodney A. Rosalia (2015)
10.3389/fimmu.2018.00325
Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity
Danielle A. Wagner-Muñiz (2018)
10.1177/001452469000101110
"J."
G.G. Stokes (1890)
10.1038/s41467-019-11157-1
Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells
W. Liu (2019)
Protein and Peptide Biomaterials for Engineered Subunit Vaccines and Immunotherapeutic Applications, Annual review of chemical and biomolecular engineering
A N Tsoras (2019)
10.1371/journal.ppat.1000058
Changing Selective Pressure during Antigenic Changes in Human Influenza H3
Benjamin P. Blackburne (2008)
10.1016/j.jconrel.2011.12.039
Towards tailored vaccine delivery: needs, challenges and perspectives.
Jean-Pierre Amorij (2012)
Skwarczynski , Multiantigenic peptide-polymer conjugates as therapeutic vaccines against cervical cancer
W M Hussein (2016)
A Randomized ,
M. Hilbink (2009)
10.4049/jimmunol.170.9.4465
Activation with CpG-A and CpG-B Oligonucleotides Reveals Two Distinct Regulatory Pathways of Type I IFN Synthesis in Human Plasmacytoid Dendritic Cells 1
M. Kerkmann (2003)
10.1016/j.cbpa.2016.05.013
Encapsulins: microbial nanocompartments with applications in biomedicine, nanobiotechnology and materials science.
Tobias W. Giessen (2016)
10.4161/hv.29589
Applications of nanomaterials as vaccine adjuvants
M. Zhu (2014)
10.1016/j.vaccine.2014.03.092
Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice.
Kamal El Bissati (2014)
10.1006/VIRO.2001.1179
Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
D. D. Da Silva (2001)
10.1186/1743-422X-6-30
Influenza virus antigenic variation, host antibody production and new approach to control epidemics
J. Chen (2008)
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected
E. Hamilton (2012)
10.1586/erv.12.92
Pre-erythrocytic malaria vaccines: identifying the targets
P. Duffy (2012)
10.1021/nn403085w
Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation.
Nicholas M. Molino (2013)
WHO influenza (seasonal). WHO
(2014)
10.1158/1078-0432.CCR-05-1900
In vitro Stimulation of CD8 and CD4 T Cells by Dendritic Cells Loaded with a Complex of Cholesterol-Bearing Hydrophobized Pullulan and NY-ESO-1 Protein: Identification of a New HLA-DR15–Binding CD4 T-Cell Epitope
Kosei Hasegawa (2006)
10.1371/journal.pone.0017642
Design of a Protective Single-Dose Intranasal Nanoparticle-Based Vaccine Platform for Respiratory Infectious Diseases
B. Ulery (2011)
10.1073/pnas.1400478111
Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants
C. Maisonneuve (2014)
10.1038/nri3488
Applications of nanotechnology for immunology
D. M. Smith (2013)
10.1371/journal.pone.0143507
Silica Vesicle Nanovaccine Formulations Stimulate Long-Term Immune Responses to the Bovine Viral Diarrhoea Virus E2 Protein
K. T. Mody (2015)
10.1016/j.carres.2014.07.012
Assembling different antennas of the gp120 high mannose-type glycans on gold nanoparticles provides superior binding to the anti-HIV antibody 2G12 than the individual antennas.
F. Chiodo (2015)
10.1016/j.jconrel.2018.12.026
Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response.
L. Niu (2019)
2nd
P. E. Makidon (2010)
10.1016/j.biomaterials.2016.03.039
Artificial bacterial biomimetic nanoparticles synergize pathogen-associated molecular patterns for vaccine efficacy.
A. Siefert (2016)
10.1080/21691401.2017.1414054
Efaverinz and nano-gold-loaded mannosylated niosomes: a host cell-targeted topical HIV-1 prophylaxis via thermogel system
Tanushree Malik (2018)
10.1208/s12248-014-9662-z
A Therapeutic Microparticle-Based Tumor Lysate Vaccine Reduces Spontaneous Metastases in Murine Breast Cancer
B. Gross (2014)
10.1016/j.vaccine.2018.05.034
Simultaneous surface display and cargo loading of encapsulin nanocompartments and their use for rational vaccine design.
P. Lagoutte (2018)
10.1086/600120
Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
K. Kester (2009)
10.1016/j.nano.2016.08.030
Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge.
Christopher P. Karch (2017)
10.1016/j.vaccine.2015.08.025
Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.
R. Kumar (2015)
10.1016/j.jaci.2012.12.1561
The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.
K. Beeh (2013)
10.1158/1078-0432.CCR-10-3126
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
M. Cheever (2011)
10.1016/j.jconrel.2013.03.025
Bioreducible alginate-poly(ethylenimine) nanogels as an antigen-delivery system robustly enhance vaccine-elicited humoral and cellular immune responses.
Ping Li (2013)
10.1016/j.nano.2013.08.005
Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines.
Li Wang (2014)
10.1371/journal.pone.0061416
Drug Synergy of Tenofovir and Nanoparticle-Based Antiretrovirals for HIV Prophylaxis
T. Chaowanachan (2013)
10.1016/j.jconrel.2015.07.029
Single-injection vaccines: Progress, challenges, and opportunities.
K. McHugh (2015)
10.1186/s12951-017-0305-2
Nanodiamond enhances immune responses in mice against recombinant HA/H7N9 protein
N. Pham (2017)
10.1046/j.1365-2222.2002.01514.x
Liposome‐entrapped D. pteronyssinus vaccination in mild asthma patients: effect of 1‐year double‐blind, placebo‐controlled trial on inflammation, bronchial hyper‐responsiveness and immediate and late bronchial responses to the allergen
M. J. Alvarez (2002)
10.1371/journal.pone.0048304
Protective Antibody and CD8+ T-Cell Responses to the Plasmodium falciparum Circumsporozoite Protein Induced by a Nanoparticle Vaccine
S. A. Kaba (2012)
10.1021/nn3057005
Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo.
K. Niikura (2013)
10.1016/j.actbio.2018.09.037
Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus.
Reshma J. Nevagi (2018)
some-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators, Pharmaceutics
S. Tandrup Schmidt (2020)
10.1007/s00262-011-0970-1
Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine
Elizabeth A. Vasievich (2011)
10.1016/j.vaccine.2012.12.077
A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing.
Fadi Saade (2013)
O
R. A. Blom (2016)
10.1016/j.vaccine.2010.07.020
Principles of vaccine design-Lessons from nature.
F. Zepp (2010)
10.1038/s41541-018-0086-0
Overcoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates
E. Bayon (2018)
10.3390/ijms17030390
Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke
J. Álvarez-Sabín (2016)
10.1002/adma.201200209
Self-assembled peptide amphiphile micelles containing a cytotoxic T-cell epitope promote a protective immune response in vivo.
M. Black (2012)
10.1021/acs.molpharmaceut.6b01088
Encapsulation of an EP67-Conjugated CTL Peptide Vaccine in Nanoscale Biodegradable Particles Increases the Efficacy of Respiratory Immunization and Affects the Magnitude and Memory Subsets of Vaccine-Generated Mucosal and Systemic CD8+ T Cells in a Diameter-Dependent Manner.
B. V. K. Karuturi (2017)
10.1007/s00430-009-0137-2
Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine
P. Makidon (2009)
10.1039/C9TB00448C
A surface charge dependent enhanced Th1 antigen-specific immune response in lymph nodes by transfersome-based nanovaccine-loaded dissolving microneedle-assisted transdermal immunization.
Xuanjin Wu (2019)
10.2147/IJN.S72264
Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
Kathleen A. Ross (2015)
10.1146/annurev-chembioeng-060718-030347
Protein and Peptide Biomaterials for Engineered Subunit Vaccines and Immunotherapeutic Applications.
Alexandra N. Tsoras (2019)
10.2147/IJN.S158536
Curdlan sulfate–O-linked quaternized chitosan nanoparticles: potential adjuvants to improve the immunogenicity of exogenous antigens via intranasal vaccination
S. Zhang (2018)
10.1016/j.it.2013.07.006
Dendritic cells and other innate determinants of T helper cell polarisation.
K. Walsh (2013)
10.1002/smll.201703207
Intranasal Nanovaccine Confers Homo- and Hetero-Subtypic Influenza Protection.
M. Qi (2018)
Biocompatible dvancements in prophylactic and therapeutic nanovaccines
P. Bhardwaj (2017)
Lipodvancements in prophylactic and therapeutic nanovaccines
P. Bhardwaj (2020)
10.1016/j.biomaterials.2012.03.041
Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype.
Stacey L. Demento (2012)
10.1111/j.1747-0285.2008.00746.x
Peptide Nanoparticles as Novel Immunogens: Design and Analysis of a Prototypic Severe Acute Respiratory Syndrome Vaccine
T. F. Pimentel (2009)
10.1515/9783110685039-030
s ? ? ? ? ? ? ? ? ?
Hung-Yu Tseng (2005)
10.1371/journal.pone.0061885
A Single-Dose PLGA Encapsulated Protective Antigen Domain 4 Nanoformulation Protects Mice against Bacillus anthracis Spore Challenge
M. Manish (2013)
10.1016/j.vaccine.2011.12.029
A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
J. Tang (2012)
10.1128/IAI.69.9.5305-5312.2001
Role of Trehalose Dimycolate in Recruitment of Cells and Modulation of Production of Cytokines and NO in Tuberculosis
V. M. Lima (2001)
10.1016/j.imbio.2017.06.002
Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines.
Félix Rueda (2017)
10.1002/jps.24161
Enhanced mucosal immune responses against tetanus toxoid using novel delivery system comprised of chitosan-functionalized gold nanoparticles and botanical adjuvant: characterization, immunogenicity, and stability assessment.
Ganesh A Barhate (2014)
10.1016/j.exppara.2012.09.001
The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen.
A. Badiee (2012)
10.3390/vaccines5010003
A Protective Vaccine against Chlamydia Genital Infection Using Vault Nanoparticles without an Added Adjuvant
Janina Jiang (2017)
10.1016/j.micpath.2020.104724
d.
Danna Zhou (2021)
10.1016/j.tibtech.2011.02.004
Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines.
Stacey L. Demento (2011)
Progress and prospects for blood-stage malaria vaccines, Expert review of vaccines
K Miura (2016)
10.1016/j.colsurfb.2009.06.025
Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition.
A. Badiee (2009)
10.1016/j.biomaterials.2012.05.041
Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope.
J. Rudra (2012)
10.1208/s12248-014-9707-3
Peptide Amphiphile Micelles Self-Adjuvant Group A Streptococcal Vaccination
Amanda Trent (2014)
10.1016/j.imlet.2017.05.002
Co-utilization of a TLR5 agonist and nano-formulation of HIV-1 vaccine candidate leads to increased vaccine immunogenicity and decreased immunogenic dose: A preliminary study.
H. Rostami (2017)
10.2217/nnm-2016-0381
Vaccine nanoparticles for protection against HIV infection.
Marisa E Aikins (2017)
A
O. Borges (2008)
10.1038/nnano.2017.52
A STING-Activating Nanovaccine for Cancer Immunotherapy
Min Luo (2017)
10.1371/journal.pone.0007611
A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon
B. Lell (2009)
10.1016/j.coi.2013.03.001
Dendritic cell-based nanovaccines for cancer immunotherapy.
L. Paulis (2013)
10.1002/adhm.201701395
Advances and Opportunities in Nanoparticle‐ and Nanomaterial‐Based Vaccines against Bacterial Infections
Leon C. W. Lin (2018)
10.1016/j.bmc.2016.07.036
Multiantigenic peptide-polymer conjugates as therapeutic vaccines against cervical cancer.
Waleed M Hussein (2016)
10.1016/j.chom.2015.02.012
Influenza vaccines: challenges and solutions.
Katherine V Houser (2015)
) fusion peptide and GM-CSF DNA elicits potent and prolonged CD8(+) T cell-dependent anti-tumor immunity in mice, Vaccine
J Tang (2012)
10.1016/j.vaccine.2017.02.040
Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants.
L. Seth (2017)
Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys, Clinical and vaccine immunology : CVI
Tussey (2015)
Towards tailored vaccine delivery: needs
J. P. Amorij (2012)
10.1021/acsnano.8b07662
Polysaccharide Nanoparticles Can Efficiently Modulate the Immune Response against an HIV Peptide Antigen
Tamara G. Dacoba (2019)
10.2147/IJN.S8428
Toxicologic effects of gold nanoparticles in vivo by different administration routes
X. Zhang (2010)
10.1016/j.copbio.2012.05.004
Vault particles: a new generation of delivery nanodevices.
A. Casañas (2012)
10.3389/fimmu.2013.00214
Vaccine Adjuvants: Mode of Action
E. de Gregorio (2013)
10.1186/1475-2875-12-136
Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine
M. E. McCoy (2013)
10.3389/fimmu.2017.00684
A Poly(Lactic-co-Glycolic) Acid Nanovaccine Based on Chimeric Peptides from Different Leishmania infantum Proteins Induces Dendritic Cells Maturation and Promotes Peptide-Specific IFNγ-Producing CD8+ T Cells Essential for the Protection against Experimental Visceral Leishmaniasis
E. Athanasiou (2017)
10.1093/trstmh/tru182
Nanoparticles modify dendritic cell homeostasis and induce non-specific effects on immunity to malaria.
S. Xiang (2015)
10.1016/j.nano.2017.08.015
Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.
K. Schulze (2017)
10.1126/SCIENCE.1100369
Cancer Immunotherapy: A Treatment for the Masses
J. Blattman (2004)
10.1172/JCI91192
T cells control the generation of nanomolar-affinity anti-glycan antibodies
Zinaida Polonskaya (2017)
10.1016/j.vaccine.2011.11.084
Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide.
W. Zollinger (2012)
10.1186/1743-422X-9-108
Immunization of mice by Hollow Mesoporous Silica Nanoparticles as carriers of Porcine Circovirus Type 2 ORF2 Protein
Huichen Guo (2012)
10.2217/nnm.13.58
Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus.
Wenqian Tao (2014)
10.2147/IJN.S218057
Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2
Peiyang Ding (2019)
10.1007/s13346-019-00652-z
Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8+ T cell immune responses
Q. Chen (2019)
10.1002/smll.201402179
In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models.
Joao Paulo Mattos Almeida (2015)
Polymeric particles in vaccine delivery, Current opinion in microbiology
A C Rice-Ficht (2010)
10.1002/adhm.201400137
Titrating T-cell epitopes within self-assembled vaccines optimizes CD4+ helper T cell and antibody outputs.
R. Pompano (2014)
10.1080/09205063.2014.940243
Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells
J. E. Vela Ramirez (2014)
10.3389/fimmu.2013.00114
Mechanisms of Action of Adjuvants
S. Awate (2013)
10.1182/blood-2011-04-345579
Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways.
M. A. Berkowska (2011)
10.1073/pnas.1121423109
Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery
David N. Nguyen (2012)
10.1021/acsami.5b05497
Lipopeptide-Coated Iron Oxide Nanoparticles as Potential Glycoconjugate-Based Synthetic Anticancer Vaccines.
Suttipun Sungsuwan (2015)
10.1021/acsnano.5b01042
Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Y. Guo (2015)
Comparison of the immune response against polio peptides covalently-surface-linked to and internally-entrapped in liposomes.
L. Tan (1991)
10.1166/JBN.2015.1942
Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.
A. Date (2015)
10.1016/j.ymeth.2013.04.014
Nanovaccines and their mode of action.
Mehfuz Zaman (2013)
10.1089/AID.2013.0076
Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau.
Victor Raúl Gómez Román (2013)
10.3389/fimmu.2019.01015
Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine
Mona O. Mohsen (2019)
10.1021/acsbiomaterials.7b00561
A Supramolecular Vaccine Platform Based on α-Helical Peptide Nanofibers.
Yaoying Wu (2017)
Liposome-entrapped D
M. J. Alvarez (2002)
10.1515/9783486731620-002
I
John B. Shoven (1824)
10.4161/21645515.2014.973317
Antigen-specific vaccines for cancer treatment
M. Tagliamonte (2014)
10.1016/j.ejpb.2008.01.019
Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
O. Borges (2008)
10.3390/pharmaceutics8010007
Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators
Signe Tandrup Schmidt (2016)
10.1016/j.jconrel.2018.04.031
Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8+ T cell responses
Youhui Si (2018)
10.1080/2162402X.2018.1541534
Pre-clinical development of Listeria-based nanovaccines as immunotherapies for solid tumours: insights from melanoma
Hector Terán-Navarro (2019)
10.1021/acscentsci.9b00060
Engineering Magnetosomes for High-Performance Cancer Vaccination
Feng Li (2019)
10.1016/j.jconrel.2012.07.012
Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response.
Randip Kaur (2012)
Single-injection vaccines: Progress
K. J. McHugh (2015)
10.1038/nri2343
How regulatory T cells work
D. Vignali (2008)
10.1073/pnas.1313152110
Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose
A. de Titta (2013)
10.3389/fimmu.2018.01496
Vectorized Delivery of Alpha-GalactosylCeramide and Tumor Antigen on Filamentous Bacteriophage fd Induces Protective Immunity by Enhancing Tumor-Specific T Cell Response
R. Sartorius (2018)
10.1002/eji.201041187
Switched memory B cells maintain specific memory independently of serum antibodies: The hepatitis B example
M. Rosado (2011)
10.3389/fimmu.2019.01349
Immunization With Mycobacterium tuberculosis Antigens Encapsulated in Phosphatidylserine Liposomes Improves Protection Afforded by BCG
G. Diogo (2019)
10.1016/j.biomaterials.2011.01.067
Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery.
Zhiping Zhang (2011)
10.1016/j.vaccine.2015.03.063
M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection.
Wenqian Tao (2015)
10.1038/s41467-019-13744-8
Artificially cloaked viral nanovaccine for cancer immunotherapy
M. Fusciello (2019)
10.1002/jbm.b.32820
Single immunization with a suboptimal antigen dose encapsulated into polyanhydride microparticles promotes high titer and avid antibody responses.
Lucas M Huntimer (2013)
10.1016/j.ijpharm.2018.07.069
The novel immunogenic chimeric peptide vaccine to elicit potent cellular and mucosal immune responses against HTLV‐1
M. Kabiri (2018)
10.3390/ijms17050666
A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines
A. Nandy (2016)
10.1371/journal.pone.0053314
Preparation and Efficacy of a Live Newcastle Disease Virus Vaccine Encapsulated in Chitosan Nanoparticles
K. Zhao (2012)
Sardvancements in prophylactic and therapeutic nanovaccines
M. Kerkmann (2003)
10.1016/j.ejps.2011.10.012
Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant.
T. Wang (2011)
Enhanced mucosal immune responses against tetanus toxoid using novel delivery system comprised of chitosanfunctionalized gold nanoparticles and botanical adjuvant: characterization
G. Barhate (2014)
10.1038/s41467-017-02725-4
Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses
L. Deng (2017)
10.1111/j.1750-2659.2011.00268.x
Quantitative review of antibody response to inactivated seasonal influenza vaccines
Jessica C. Seidman (2012)
10.3389/fcimb.2013.00013
Vaccine delivery using nanoparticles
A. Gregory (2013)
10.1016/j.jconrel.2010.03.027
Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response.
M. Henriksen-Lacey (2010)
10.1021/acsami.8b20364
A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
X. Dong (2019)
10.1002/chem.201400256
A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer.
M. Glaffig (2014)
10.3389/fimmu.2016.00171
Heat Shock Protein–Peptide and HSP-Based Immunotherapies for the Treatment of Cancer
M. Shevtsov (2016)
10.1098/rstb.2013.0433
The contribution of vaccination to global health: past, present and future
B. Greenwood (2014)
10.1242/jcs.121814
Poly(lactide-co-glycolide)-rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG infection in macrophages and remain membrane-bound in phago-lysosomes
Raja Kalluru (2013)
10.1016/j.nano.2017.11.009
Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses.
N. Climent (2018)
10.1038/s41565-018-0271-3
A Malaria Vaccine Adjuvant Based on Recombinant Antigen Binding to Liposomes
Wei-Chiao Huang (2018)
chitosan nanoparticles as an efficient delivery vehicle for Mycobacterium tuberculosis lipids to induce potent cytokines and antibody response through activation of gammadelta T cells in mice
(2017)
Nanovaccines for Please cite this article
P. Bhardwaj (2015)
10.1158/1078-0432.CCR-17-3811
Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model
F. Nguyen (2018)
10.1016/j.nano.2016.09.001
Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.
L. Wang (2017)
10.1038/ni.2703
Innate and adaptive immune cells in the tumor microenvironment
T. Gajewski (2013)
10.1038/ni.2039
Immunological mechanisms of vaccination
B. Pulendran (2011)
10.1023/A:1011043230573
In Vitro Protein Release and Degradation of Poly-dl-lactide-poly(ethylene glycol) Microspheres with Entrapped Human Serum Albumin: Quantitative Evaluation of the Factors Involved in Protein Release Phases
X. Li (2004)
10.1111/j.1747-0285.2012.01423.x
Conformation‐specific Display of 4E10 and 2F5 Epitopes on Self‐assembling Protein Nanoparticles as a Potential HIV Vaccine
Newton Wahome (2012)
10.1016/j.vaccine.2010.01.011
Chitosan-based nanoparticles for improving immunization against hepatitis B infection.
C. Prego (2010)
10.3389/fimmu.2013.00245
Treg Inducing Adjuvants for Therapeutic Vaccination Against Chronic Inflammatory Diseases
C. Keijzer (2013)
10.1111/j.1365-2567.2005.02268.x
Enhanced and prolonged cross‐presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles
H. Shen (2006)
10.1385/IR:24:1:53
Cellular immunity and memory to respiratory virus infections
D. Woodland (2001)
10.1128/CVI.00770-14
Immunogenicity and Efficacy of Flagellin-Envelope Fusion Dengue Vaccines in Mice and Monkeys
Ge Liu (2015)
10.1021/acsbiomaterials.6b00532
Viruslike Particles Encapsidating Respiratory Syncytial Virus M and M2 Proteins Induce Robust T Cell Responses.
B. Schwarz (2016)
Heatshock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II
O. Bloch (2014)
10.1016/j.vaccine.2014.10.036
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.
J. V. van Dissel (2014)
10.2217/fvl-2018-0174
Glycosylation of the HIV-1 Env V1V2 loop to form a native-like structure may not be essential with a nanoparticle vaccine
Christopher P. Karch (2019)
10.1016/j.jim.2018.06.009
Immunization with tumor neoantigens displayed on T7 phage nanoparticles elicits plasma antibody and vaccine-draining lymph node B cell responses.
G. Shukla (2018)
10.3109/10409239109086790
The cell biology of antigen processing.
T. Levine (1991)
10.1007/s00109-011-0757-z
Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a “one size fits all” approach?
X. Clemente-Casares (2011)
10.1021/acschembio.8b00313
Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice.
Zhaojun Yin (2018)
10.1021/acsami.8b10948
Amantadine Surface-Modified Silver Nanorods Improves Immunotherapy of HIV Vaccine Against HIV-Infected Cells.
W. Li (2018)
10.1586/14760584.2016.1141680
Progress and prospects for blood-stage malaria vaccines
K. Miura (2016)
10.1021/acsnano.7b04955
Biomimetic Magnetosomes as Versatile Artificial Antigen-Presenting Cells to Potentiate T-Cell-Based Anticancer Therapy.
Qianmei Zhang (2017)
10.1038/nbt1332
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
S. T. Reddy (2007)
Multidrug and extensively drug-resistant TB (M/XDR-TB): problems and solutions.
R. Prasad (2010)
10.1371/journal.pone.0022889
RD Antigen Based Nanovaccine Imparts Long Term Protection by Inducing Memory Response against Experimental Murine Tuberculosis
M. A. Ansari (2011)
10.1021/mp100255c
Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine.
Chandan Thomas (2011)
10.1007/s10875-013-9949-3
A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults
J. Montoya (2013)
10.1016/j.ijpharm.2016.09.057
Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.
Nirmal Marasini (2016)
10.1016/j.antiviral.2012.09.015
Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.
A. Date (2012)
10.1186/1471-2407-11-430
INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
Y. Wu (2011)
10.1371/journal.pone.0006465
Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area
Mark E. Polhemus (2009)
10.1155/2011/126794
A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection
S. Babapoor (2011)
Influenza virus antigenic variation
J. Chen (2009)
10.1172/jci.insight.85955
Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii.
Kamal El Bissati (2016)
10.1002/anie.201804067
Cubosomes: The Next Generation of Smart Lipid Nanoparticles?
H. Barriga (2019)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar